EX-10.13



 Exhibit 10.13 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

  
 PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT – EXCLUSIVE 

COVER PAGE 
 For PHS internal use
only: 
 License Number: 
 L-127-2007/0 
 License Application Number: A-052-2007 
 Serial Number(s) of Licensed Patent(s) or Patent Application(s): 
 [*] 

Licensee: 
 GlobeImmune 
 1450 Infinite Drive 

Louisville, CO 80027 
 Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): 
 N/A 
 Additional Remarks: 
 Public Benefit(s): 
 Licensee agrees, after its First Commercial
Sale, to use its reasonable commercial efforts to make reasonable quantities of Licensed Product(s) or materials produced through the use of Licensed Process(es) available on a compassionate use basis to indigent patients subject
to availability, either through the patient’s physician(s) and/or the medical center treating the patient; provided, however, that such requirement shall not substantially keep the Licensee from commercializing the Licensed
Product(s); and 
 Licensee further agrees, after its First Commercial Sale and as part of its marketing and
product promotion, to use its reasonable commercials efforts to develop written educational materials (e.g., brochures, advertisements, etc.) directed to patients and physicians detailing the Licensed Product(s) and/or medical aspects of the
prophylactic and therapeutic uses of the Licensed Product(s). 
  Page
 1
 of 27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 








 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of
this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E
(Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are: 
  

	 	1)	The National Institutes of Health (“NIH”) or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to
as “PHS”, agencies of the United States Public Health Service within the Department of Health and Human Services (“HHS”); and 


 

	 	2)	The person, corporation, or institution identified above or on the Signature Page, having offices at the address indicated on the Signature Page, hereinafter referred
to as “Licensee”. 


  
 Page 2 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 PHS PATENT LICENSE AGREEMENT – EXCLUSIVE 

PHS and Licensee agree as follows: 
  

	1.	BACKGROUND  

  

	 	1.1	In the course of conducting biomedical and behavioral research, PHS investigators made inventions that may have commercial applicability.


  

	 	1.2	By assignment of rights from PHS employees and other inventors, HHS, on behalf of the Government, owns intellectual property rights claimed in any
United States or foreign patent applications or patents corresponding to the assigned inventions. HHS also owns any tangible embodiments of these inventions actually reduced to practice by PHS. 


 

	 	1.3	The Secretary of HHS has delegated to PHS the authority to enter into this Agreement for the licensing of rights to these inventions.


  

	 	1.4	PHS desires to transfer these inventions to the private sector through commercialization licenses to facilitate the commercial development of products and
processes for public use and benefit. 

  

	 	1.5	Licensee desires to acquire commercialization rights to certain of these inventions in order to develop processes, methods, or marketable products for public use
and benefit. 

  

	2.	DEFINITIONS 

  

	 	2.1	“Benchmarks” mean the performance milestones that are set forth in Appendix D. 


 

	 	2.2	“Commercial Development Plan” means the written commercialization plan attached as Appendix E. 


 

	 	2.3	“First Commercial Sale” means the initial transfer after marketing approval by FDA or by a foreign equivalent, including, if applicable, but without
limitation pricing approvals, by or on behalf of Licensee or its sublicensees of Licensed Products or the initial practice of a Licensed Process by or on behalf of Licensee or its sublicensees in exchange for cash or some
equivalent to which value can be assigned for the purpose of determining Net Sales. 

  

	 	2.4	“Government” means the Government of the United States of America. 


 

	 	2.5	“Licensed Fields of Use” means the fields of use identified in Appendix B. 


 

	 	2.6	“Licensed Patent Rights” shall mean: 

  

	 	(a)	Patent applications (including provisional patent applications and PCT patent applications) or patents listed in Appendix A, all divisions , continuations, and continuations-in-part of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of
these patents; 

  

	 	(b)	to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a): 


 

	 	(i)	continuations-in-part of 2.6(a); 


  
 Page 3 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(ii)	all divisions and continuations of these continuations-in-part;


  

	 	(iii)	all patents issuing from these continuations-in-part, divisions, and continuations;


  

	 	(iv)	priority patent application(s) of 2.6(a); and 

  

	 	(v)	any reissues, reexaminations, and extensions of these patents; 

  

	 	(c)	to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.6(a): all counterpart foreign and U.S. patent
applications and patents to 2.6(a) and 2.6(b), including those listed in Appendix A; and, 

  

	 	(d)	Licensed Patent Rights shall not include 2.6(b) or 2.6(c) to the extent that they contain one or more claims directed to new matter which is not the
subject matter disclosed in 2.6(a). 

  

	 	2.7	“Licensed Processes” means processes which, in the course of being practiced, would be within the scope of one or more claims of the Licensed Patent
Rights that have not expired or been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 


 

	 	2.8	“Licensed Products” means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more
claims of the Licensed Patent Rights that have not expired or been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction. 


 

	 	2.9	“Licensed Territory” means the geographical area identified in Appendix B. 


 

	 	2.10	“Net Sales” means [*] 

  

	 	2.11	“Practical Application” means to manufacture in the case of a composition or product, to practice in the case of a process or method, or to operate in
the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or Government regulations available to the public on
reasonable terms. 

  

	 	2.12	“Research License” means a nontransferable, nonexclusive license to make and to use Licensed Products or Licensed Processes as defined by
the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

  

	 	2.13	“Affiliate” means a corporation or other business entity which directly or indirectly is controlled by or controls, or is under common control with
Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the corporation or other business entity, or the power to elect or appoint
more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

  

	 	2.14	“Distributor” shall mean a third party which purchases Licensed Product(s) from Licensee or one of its Affiliate(s) or
Sublicensee(s) for further re-sale, but which does not have a sublicense to manufacture Licensed Product(s), except to the extent such a sublicense is necessary for such third party (i) to
perform final packaging of Licensed Product(s) and/or (ii) to enable a regulatory filing and/or to conduct a confirmatory clinical trial of a Licensed Product(s) to support a regulatory filing in such third party’s territory
after such Licensed Product(s) has been approved in a major market. 


  
 Page 4 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	3.	GRANT OF RIGHTS 

  

	 	3.1	PHS hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent
Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any
Licensed Processes in the Licensed Fields of Use. 

  

	 	3.2	This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of PHS other than the
Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

  

	4.	SUBLICENSING 

  

	 	4.1	Upon written approval by PHS, Licensee may enter into sublicensing agreements under the Licensed Patent Rights, such approval will not be
unreasonably delayed or withheld, unless the provisions set forth in Paragraph 4.2 below are not included and/or otherwise made binding upon the sublicensee. For purposes of clarification, PHS agrees that modification of the terms of this
Agreement will not be a condition for approval by PHS for Licensee to enter into sublicensing agreements. Licensee shall provide written notice to PHS in the event Licensee desires to grant a sublicense to a
third party to develop or commercialize a License Product. In the event that PHS does not provide a written objection to Licensee within ten (10) business days of receiving notice under the preceding sentence, PHS
shall be deemed to have given its approval to the sublicense arrangement described in the notice. 

  

	 	4.2	Licensee agrees that any sublicenses granted by it shall provide that the obligations to PHS of Paragraphs
5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.7-13.9 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement. Licensee further agrees to attach
copies of these Paragraphs to all sublicense agreements. 

  

	 	4.3	Any sublicenses granted by Licensee shall provide for the termination of the sublicense, or the conversion to a license directly between the sublicensees and
PHS, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to PHS approval and contingent upon acceptance by the sublicensee of the remaining provisions of this
Agreement. 

  

	 	4.4	Licensee agrees to forward to PHS a complete copy of each fully executed sublicense agreement, postmarked within thirty (30) days of the execution of
the agreement. To the extent permitted by law, PHS agrees to maintain each sublicense agreement in confidence. 

  

	5.	STATUTORY AND PHS REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

  

	 	5.1    (a)	PHS reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed
under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which the
Government is a signatory. Prior to the First Commercial Sale, Licensee agrees to provide PHS with reasonable quantities of Licensed Products or materials made through the Licensed Processes for PHS
research use; and 


  
 Page 5 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(b)	In the event that the Licensed Patent Rights are Subject Inventions made under a Cooperative Research and Development Agreement (CRADA),
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice Licensed Patent Rights or have
Licensed Patent Rights practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that is
privileged or confidential within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale,
Licensee agrees to provide PHS reasonable quantities of Licensed Products or materials made through the Licensed Processes for PHS research use. 


 

	 	5.2	Licensee agrees that products used or sold in the United States embodying Licensed Products or produced through use of Licensed Processes shall be
manufactured substantially in the United States, unless a written waiver is obtained in advance from PHS. 

  

	 	5.3	Licensee acknowledges that PHS may enter into future CRADAs under the Federal Technology Transfer Act of 1986 that relate to the subject matter of
this Agreement. Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with PHS when acquiring these rights is necessary in order to make a CRADA project feasible.
Licensee may request an opportunity to join as a party to the proposed CRADA. 

  

	 	5.4    (a)	In addition to the reserved license of Paragraph 5.1, PHS reserves the right to grant Research Licenses directly or to require Licensee to grant
Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In order to safeguard the Licensed Patent Rights, however,
PHS shall consult with Licensee before granting to commercial entities a Research License or providing to them research samples of materials made through the Licensed Processes; and 


 

	 	(b)	In exceptional circumstances, and in the event that Licensed Patent Rights are Subject Inventions made under a CRADA, the Government, pursuant to
15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the Licensed Patent Rights in the Licensed Field of
Use on terms that are reasonable under the circumstances, or if Licensee fails to grant this license, the Government retains the right to grant the license itself. The exercise of these rights by the Government shall only be
in exceptional circumstances and only if the Government determines: 

  

	 	(i)	the action is necessary to meet health or safety needs that are not reasonably satisfied by Licensee; 


 

	 	(ii)	the action is necessary to meet requirements for public use specified by Federal regulations, and these requirements are not reasonably satisfied by the
Licensee; or 


  
 Page 6 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(iii)	the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C. §3710a(c)(4)(B); and 


 

	 	(c)	The determination made by the Government under this Paragraph 5.4 is subject to administrative appeal and judicial review under 35 U.S.C. §203(2).


  

	6.	ROYALTIES AND REIMBURSEMENT 

  

	 	6.1	Licensee agrees to pay PHS [*] 

  

	 	6.2	Licensee agrees to pay PHS a nonrefundable minimum annual royalty as set forth in Appendix C. 


 

	 	6.3	Licensee agrees to pay PHS earned royalties as set forth in Appendix C. 


 

	 	6.4	Licensee agrees to pay PHS benchmark royalties as set forth in Appendix C. 


 

	 	6.5	Licensee agrees to pay PHS [*] 

  

	 	6.6	A patent or patent application licensed under this Agreement shall cease to fall within the Licensed Patent Rights for the purpose of computing earned
royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	the application has been abandoned and not continued; 

  

	 	(b)	the application has been pending for [*] after the Effective Date of the Agreement. However, should the application issue the patent will fall within the
Licensed Patent Rights for the purpose of computing earned royalty payments; 

  

	 	(c)	the patent expires or irrevocably lapses, or 

  

	 	(d)	the claim has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency.


  

	 	6.7	No multiple royalties shall be payable because any Licensed Products or Licensed Processes are covered by more than one of the Licensed Patent
Rights. 

  

	 	6.8	On sales of Licensed Products by Licensee to [*] 

  

	 	6.9	With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the
Licensed Patent Rights and incurred by PHS prior to the Effective Date of this Agreement, [*] 

  

	 	6.10	With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the
Licensed Patent Rights incurred by PHS on or after the Effective Date of this Agreement, PHS, at its sole option, may require Licensee: 


 

	 	(a)	[*] 


  
 Page 7 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	6.11	PHS agrees, upon written request, to provide Licensee with summaries of patent prosecution invoices for which PHS has requested payment from the
Licensee under Paragraphs 6.9 and 6.10. 

  

	 	6.12	Licensee may elect to surrender its rights in any country of the Licensed Territory under any of the Licensed Patent Rights upon ninety
(90) days written notice to PHS and owe no payment obligation under Paragraph 6.10 for patent-related expenses incurred in that country after ninety (90) days of the Effective Date of the written notice.


  

	7.	PATENT FILING, PROSECUTION, AND MAINTENANCE  

  

	 	7.1	Except as otherwise provided in this Article 7, PHS agrees to take responsibility for all aspects of the preparation, filing, prosecution, and maintenance of any
and all patent applications or patents included in the Licensed Patent Rights; provided that PHS shall, on an ongoing basis, promptly furnish to Licensee copies of relevant patent-related documents in order to provide
Licensee an opportunity to provide comments regarding such documents to PHS. In the event that Licensee provides comments to PHS, PHS will consider such comments in good faith and, if reasonable, revise such
documents to include Licensee’s comments. 

  

	 	7.2	At any time, PHS may provide Licensee with written notice that PHS wishes to assume control of the preparation, filing, prosecution, and
maintenance of any and all patent applications or patents included in the Licensed Patent Rights. If PHS elects to reassume these responsibilities, Licensee agrees to cooperate fully with PHS, its attorneys, and agents in
the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and to provide PHS with complete copies of any and all documents or other materials that
PHS deems necessary to undertake such responsibilities. Licensee shall be responsible for all costs associated with transferring patent prosecution responsibilities to an attorney or agent of PHS’ choice.


  

	 	7.3	Each party shall promptly inform the other as to all matters that come to its attention that may affect the preparation, filing, prosecution, or maintenance of the
Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of Licensed Patent Rights, which comments and suggestions shall be considered by the
other party. 

  

	8.	RECORD KEEPING 

  

	 	8.1	Licensee agrees to keep accurate and correct records of Licensed Products made, used, sold, or imported and Licensed Processes practiced under this
Agreement appropriate to determine the amount of royalties due PHS. These records shall be retained for at least five (5) years following a given reporting period and shall be available during normal business hours for inspection,
at the expense of PHS, by an accountant or other designated auditor selected by PHS for the sole purpose of verifying reports and royalty payments hereunder. The accountant or auditor shall only disclose to PHS information
relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of [*] for any [*] period, then [*] at the time Licensee pays the unreported
royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within thirty (30) days of the date PHS provides Licensee notice of the payment due.



  
 Page 8 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	8.2	Beginning after the First Commercial Sale, Licensee agrees to have an audit of sales and royalties conducted by an independent auditor that is paid for by
PHS at least every two (2) years if annual sales of the Licensed Products or Licensed Processes are over [*]. The audit shall address, at a minimum, the amount of gross sales by or on behalf of Licensee during the
audit period, terms of the license as to percentage or fixed royalty to be remitted to the Government, the amount of royalties owed to the Government under this Agreement, and whether the royalties owed have been paid to the Government
and is reflected in the records of the Licensee. The audit shall also indicate the PHS license number, product, and the time period being audited. A report certified by the auditor shall be submitted promptly by the auditor directly to
PHS on completion. [*]. 

  

	9.	REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS  

  

	 	9.1	Prior to signing this Agreement, Licensee has provided PHS with the Commercial Development Plan in Appendix E, under which Licensee
intends to bring the subject matter of the Licensed Patent Rights to the point of Practical Application. This Commercial Development Plan is hereby incorporated by reference into this Agreement. Based on this plan,
performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	Licensee shall provide written annual reports on its product development progress or efforts to commercialize under the Commercial Development Plan for
each of the Licensed Fields of Use within sixty (60) days after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and development, status of applications for
regulatory approvals, manufacturing, sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. PHS also encourages these reports to include information on any of
Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress differs from that projected in the Commercial Development Plan and Benchmarks, Licensee shall explain the
reasons for these differences. In the annual report, Licensee may propose amendments to the Commercial Development Plan, acceptance of which by PHS may not be denied unreasonably. Licensee agrees to provide any additional
information reasonably required by PHS to evaluate Licensee’s performance under this Agreement. Licensee may amend the Benchmarks at any time upon written approval by PHS. PHS shall not
unreasonably withhold approval of any request of Licensee to extend the time periods of this schedule if the request is supported by a reasonable showing by Licensee of diligence in its performance under the Commercial Development
Plan and toward bringing the Licensed Products to the point of Practical Application as defined in 37 CFR §404.3(d). Licensee shall amend the Commercial Development Plan and Benchmarks at the request of
PHS to address any Licensed Fields of Use not specifically addressed in the plan originally submitted. 

  

	 	9.3	Licensee shall report to PHS the dates for achieving Benchmarks specified in Appendix C and the First Commercial Sale in each country in the
Licensed Territory within thirty (30) days of such occurrences. 

  

	 	9.4	Beginning after the First Commercial Sale, Licensee shall submit to P115, within sixty (60) days after each calendar half-year ending June 30
and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf of
Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, Licensee shall submit payment of earned royalties due. If no earned royalties are
due to PHS for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of Licensee and shall include a detailed listing of all deductions made under Paragraph
2.10 to determine Net Sales made under Article 6 to determine royalties due. 


  
 Page 9 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	9.5	Licensee agrees to forward semi-annually to PHS a copy of these reports received by Licensee from its sublicensees during the preceding half-year
period as shall be pertinent to a royalty accounting to PHS by Licensee for activities under the sublicense. 

  

	 	9.6	Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For conversion of foreign currency to U.S. dollars, the
conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars
shall be paid entirely by Licensee. The royalty report required by Paragraph 9.4 shall be mailed to PHS at its address for Agreement Notices indicated on the Signature Page. 


 

	 	9.7	Licensee shall be solely responsible for determining if any tax on royalty income is owed outside the United States and shall pay the tax and be responsible for
all filings with appropriate agencies of foreign governments. 

  

	 	9.8	Additional royalties may be assessed by PHS on any payment that is more than [*] overdue at the rate of [*]. This [*] rate may be applied retroactively from the
original due date until the date of receipt by PHS of the overdue payment and additional royalties. The payment of any additional royalties shall not prevent PHS from exercising any other rights it may have as a consequence of the
lateness of any payment. 

  

	 	9.9	All plans and reports required by this Article 9 and marked “confidential” by Licensee shall, to the extent permitted by law, be treated by PHS
as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the PHS under the Freedom of Information Act (FOIA), 5 U.S.C. §552 shall be subject to the
predisclosure notification requirements of 45 CFR §5.65(d). 

  

	10.	PERFORMANCE 

  

	 	10.1	Licensee shall use its reasonable commercial efforts to bring the Licensed Products and Licensed Processes to Practical Application, where
“reasonable commercial efforts” means efforts that are consistent with those made by a business of similar size and resources, in a similar circumstance and context, to achieve a particular result in a timely manner in accordance with the
Commercial Development Plan in Appendix E and with the intention to satisfy the time-based Benchmarks listed in Appendix D, as modified from time to time by the parties, but shall not require Licensee to take actions that would
be commercially unreasonable. The efforts of a sublicensee shall be considered the efforts of Licensee. 

  

	 	10.2	Upon the First Commercial Sale, until the expiration or termination of this Agreement, Licensee shall use its reasonable commercial efforts to make
Licensed Products and Licensed Processes reasonably accessible to the United States public. 

  

	 	10.3	Licensee agrees, after its First Commercial Sale, to use its reasonable commercial efforts to make reasonable quantities of Licensed Products or
materials produced through the use of Licensed Processes available on a compassionate use basis to patients, either through the patient’s physician(s) or the medical center treating the patient. 


 

	 	10.4	Licensee agrees, after its First Commercial Sale and as part of its marketing and product promotion, to use its reasonable commercial efforts to develop
educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products. 


  
 Page 10 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	10.5	Licensee agrees, after the First Commercial Sale, to use its reasonable commercial efforts to supply, to the Mailing Address for Agreement Notices
indicated on the Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or Licensed Processes or their packaging for educational and display purposes only. 


 

	11.	INFRINGEMENT AND PATENT ENFORCEMENT 

  

	 	11.1	PHS and Licensee agree to notify each other promptly of each infringement or possible infringement of the Licensed Patent Rights, as well as, any
facts which may affect the validity, scope, or enforceability of the Licensed Patent Rights of which either party becomes aware. 

  

	 	11.2	Pursuant to this Agreement and the provisions of Chapter 29 of Title 35, United States Code, Licensee may: 


 

	 	(a)	bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid claims in the Licensed Patent Rights;


  

	 	(b)	in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; or 


 

	 	(c)	settle any claim or suit for infringement of the Licensed Patent Rights provided, however, that PHS and appropriate Government authorities shall
have the first right to take such actions; and 

  

	 	(d)	If Licensee desires to initiate a suit for patent infringement, Licensee shall notify PHS in writing. If PHS does not notify Licensee
of its intent to pursue legal action within ninety (90) days, Licensee shall be free to initiate suit. PHS shall have a continuing right to intervene in the suit. Licensee shall take no action to compel the
Government either to initiate or to join in any suit for patent infringement, but Licensee may request the Government to initiate or join in any suit if necessary to avoid dismissal of the suit and if, after such a request,
Government does not join such suit and, as a result, such suit is dismissed, the parties shall negotiate in good faith to reduce Licensee’s financial obligations under Paragraphs 6.2 – 6.4 proportional to the economic
loss due to dismissal of the suit, as appropriate. Should the Government be made a party to any suit, Licensee shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the
motion or other action, including all costs incurred by the Government in opposing the motion or other action. In all cases, Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation. Before
Licensee commences an infringement action, Licensee shall notify PHS and give careful consideration to the views of PHS and to any potential effects of the litigation on the public health in deciding whether to bring
suit. 

  

	 	11.3	In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the Licensed Patent
Rights shall be brought against Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by Licensee under Paragraph 11.2, pursuant to this Agreement and the provisions of Chapter 29
of Title 35, United States Code or other statutes, Licensee may: 

  

	 	(a)	defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the Licensed Patent Rights; 


  
 Page 11 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(b)	in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; and


  

	 	(c)	settle any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided, however, that PHS and appropriate Government
authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and 


  
 Page 12 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(d)	If PHS does not notify Licensee of its intent to respond to the legal action within a reasonable time, Licensee shall be free to do so.
Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action, but Licensee may request the Government to initiate or to join any suit if necessary to avoid
dismissal of the suit and if after such a request, Government does not initiate or join such suit and, as a result, such suit is dismissed, the parties shall negotiate in good faith to reduce Licensee’s financial obligations under
Paragraphs 6.2 – 6.4 proportional to the economic loss due to dismissal of the suit, as appropriate Should the Government be made a party to any suit by motion or any other action of Licensee, Licensee shall reimburse the
Government for any costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If Licensee elects not to defend against the declaratory judgment action, PHS, at its option, may do so
at its own expense. In all cases, Licensee agrees to keep PHS reasonably apprised of the status and progress of any litigation. Before Licensee commences an infringement action, Licensee shall notify PHS and give
careful consideration to the views of PHS and to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.4	In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and disbursements, shall be paid by Licensee. The value of any
recovery made by Licensee through court judgment or settlement [*]. 

  

	 	11.5	PHS shall cooperate fully with Licensee in connection with any action under Paragraphs 11.2 or 11.3. PHS agrees promptly to provide access to all
necessary documents and to render reasonable assistance in response to a request by Licensee. 

  

	12.	NEGATION OF WARRANTIES AND INDEMNIFICATION 

  

	 	12.1	PHS offers no warranties other than, as specified in Article 1, (i) HHS, by assignment of rights from PHS employees and other inventors, on
behalf of the Government, owns all intellectual property rights claimed in the United States and foreign patent applications and patents in the Licensed Patent Rights, (ii) HHS owns tangible embodiments of inventions
actually reduced to practice, and (iii) PHS has the authority, by delegation from the Secretary of HHS, to enter into this Agreement. 


 

	 	12.2	PHS does not warrant the validity of the Licensed Patent Rights and makes no representations whatsoever with regard to the scope of the Licensed Patent
Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties. 


 

	 	12.3	PHS MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED
PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

	 	12.4	PHS does not represent that it shall commence legal actions against third parties infringing the Licensed Patent Rights. 


 

	 	12.5	Licensee shall indemnify and hold PHS, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands,
damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of: 


  
 Page 13 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(a)	the use by or on behalf of Licensee, its sublicensees, directors, or employees (“Licensee Parties”) of any Licensed Patent Rights; or


  

	 	(b)	the design, manufacture, distribution, or use by Licensee Parties of any Licensed Products, Licensed Processes, or other products or processes
developed by Licensee Parties in connection with or arising out of the Licensed Patent Rights. 

  

	 	12.6	Licensee agrees to maintain a liability insurance program consistent with sound business practices for a business of similar size and resources, in a similar
circumstance and context. 

  

	13.	TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

  

	 	13.1	This Agreement is effective (“Effective Date”)when signed by all parties, unless the provisions of Paragraph 14.17 are not fulfilled, and shall
extend to the expiration or termination of the last to expire of the Licensed Patent Rights unless sooner terminated as provided in this Article 13. 


 

	 	13.2	In the event that Licensee is in material default in the performance of any material obligations under this Agreement, including but not limited to the
obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, PHS may terminate this Agreement by written notice and pursue outstanding
royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	In the event that Licensee becomes insolvent, files a petition in bankruptcy, has such a petition filed against it, determines to file a petition in bankruptcy,
or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, Licensee shall immediately notify PHS in writing. Furthermore, PHS shall have the right to terminate this Agreement
immediately upon Licensee’s receipt of written notice. 

  

	 	13.4	Licensee shall have a unilateral right to terminate this Agreement or any licenses in any country or territory by giving PHS sixty (60) days
written notice to that effect. 

  

	 	13.5	Subject to Paragraph 13.5, PHS shall specifically have the right to terminate or modify, at its option, this Agreement, if PHS determines that the
Licensee: 

  

	 	(a)	is not executing the Commercial Development Plan and the Licensee cannot otherwise demonstrate to PHS’ satisfaction that the Licensee
has taken, or can be expected to take within a reasonable time, effective steps to achieve Practical Application of the Licensed Products or Licensed Processes; 


 

	 	(b)	has not achieved the Benchmarks as may be modified under Paragraph 9.2; 


 

	 	(c)	has willfully made a false statement of, or willfully omitted a material fact in the license application or in any report required by the license Agreement;


  

	 	(d)	has committed a material breach of a material covenant or material agreement contained in this Agreement; 


 

	 	(e)	is not keeping Licensed Products or Licensed Processes reasonably available to the public after commercial use commences; 


 

	 	(f)	cannot, after First Commercial Sale, reasonable satisfy unmet health and safety needs; or 


  
 Page 14 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	(g)	cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless waived. 


 

	 	13.6	In making the determination referenced in Paragraph 13.5, PHS shall take into account the normal course of such commercial development programs conducted with
sound and reasonable business practices and judgment and the annual reports submitted by Licensee under Paragraph 9.2. Prior to invoking termination or modification of this Agreement under Paragraph 13.5, PHS shall give written
notice to Licensee providing Licensee specific notice of, and a ninety (90) day opportunity to respond to, PHS’ concerns as to the items referenced in 13.5(a)-13.5(g). If Licensee fails to alleviate
PHS’ concerns as to the items referenced in 13.5(a)-13.5(g) or fails to initiate corrective action to PHS’ satisfaction, PHS, subject to Paragraph 13.8, may modify or terminate this Agreement.


  

	 	13.7	When the public health and safety so require, and after written notice to Licensee providing Licensee a sixty (60) day opportunity to respond,
PHS shall have the right to require Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent Rights, unless Licensee can reasonably
demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. PHS shall not require the granting of a sublicense unless the responsible
applicant has first negotiated in good faith with Licensee. 

  

	 	13.8	Subject to Paragraph 13.8, PHS reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this Agreement if it is determined that
this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by Licensee. 


 

	 	13.9	Within thirty (30) days of receipt of written notice of PHS’ unilateral decision to modify or terminate this Agreement, Licensee may,
consistent with the provisions of 37 CFR §404.11, appeal the decision by written submission to the designated PHS official. The decision of the designated PHS official shall be the final agency decision. Licensee may
thereafter exercise any and all administrative or judicial remedies that may be available. 

  

	 	13.10	Within ninety (90) days of expiration or termination of this Agreement under this Article 13, a final report shall be submitted by Licensee. Any
royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expense, due to PHS shall become immediately due and payable upon termination or expiration. If terminated
under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with PHS pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this Agreement, upon termination or expiration of this
Agreement, Licensee shall return all Licensed Products or other materials included within the Licensed Patent Rights to PHS or provide PHS with certification of the destruction thereof.



  
 Page 15 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	14.	GENERAL PROVISIONS 

  

	 	14.1	Neither party may waive or release any of its rights or interests in this Agreement except in writing. The failure of the Government to assert a right
hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by the Government or excuse a similar subsequent failure to perform any of these terms or conditions by
Licensee. 

  

	 	14.2	This Agreement constitutes the entire agreement between the parties relating to the subject matter of the Licensed Patent Rights, Licensed Products
and Licensed Processes, and all prior and contemporaneous negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this Agreement. 


 

	 	14.3	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable
under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement; provided that no such severability shall be effective if it materially changes the
economic benefit of this Agreement to either Party. 

  

	 	14.4	If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of the proposed modification by the party desiring the
change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or their designees. 


 

	 	14.5	The construction, validity, performance, and effect of this Agreement shall be governed by Federal law as applied by the Federal courts in the District of
Columbia. 

  

	 	14.6	All Agreement notices required or permitted by this Agreement shall be given by prepaid, first class, registered or certified mail or by an
express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party.
Agreement notices shall be considered timely if the notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial
carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.


  

	 	14.7	This Agreement shall not be assigned by Licensee except: 

  

	 	(a)	with the prior written consent of PHS, this consent shall not to be withheld unreasonably; or 


 

	 	(b)	as part of a sale or transfer of substantially the entire business of Licensee relating to operations which concern this Agreement.


  

	 	14.8	Licensee shall notify PHS within ten (10) days of any assignment of this Agreement by Licensee. 


 

  
 Page 16 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	14.9	Licensee agrees in its use of any PHS-supplied materials to comply with all applicable statutes, regulations, and
guidelines, including PHS and IRIS regulations and guidelines. Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States without complying with 21 CFR Part 50 and 45 CFR Part
46. Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying PHS, in writing, of the research or trials and complying with the applicable
regulations of the appropriate national control authorities. Written notification to PHS of research involving human subjects or clinical trials outside of the United States shall be given no later than sixty (60) days prior to
commencement of the research or trials. 	 

  

	 	14.10	Licensee acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including the Export Administration Act of 1979 and
Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may require a license from the appropriate agency of the U.S.
Government or written assurances by Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. PHS neither represents that a license is or is not required or that, if
required, it shall be issued. 	 

  

	 	14.11	Licensee agrees, in accordance with applicable law, to mark the Licensed Products or their packaging sold in the United States with all applicable U.S.
patent numbers and similarly to indicate “Patent Pending” status. All Licensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner consistent with applicable law to preserve PHS patent
rights in those countries. 	 

  

	 	14.12	By entering into this Agreement, PHS does not directly or indirectly endorse any product or service provided, or to be provided, by Licensee
whether directly or indirectly related to this Agreement. Licensee shall not state or imply that this Agreement is an endorsement by the Government, PHS, any other Government organizational unit, or any
Government employee. Additionally, Licensee shall not use the names of NIH, FDA, PHS, or HHS or the Government or their employees in any advertising, promotional, or sales literature without the prior
written approval of PHS. 	 

  

	 	14.13	The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or a breach of this Agreement, except for appeals of
modifications or termination decisions provided for in Article 13. Licensee agrees first to appeal any unsettled claims or controversies to the designated PHS official, or designee, whose decision shall be considered the final agency
decision. Thereafter, Licensee may exercise any administrative or judicial remedies that may be available. 	 

  
  

	 	14.14	Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person any immunity from or defenses under the antitrust laws or
from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 CFR Part 404 shall not be immunized from the operation of state or Federal law by reason of the source of the grant. 	 

  

	 	14.15	Any formal recordation of this Agreement required by the laws of any Licensed Territory as a prerequisite to enforceability of the Agreement in the
courts of any foreign jurisdiction or for other reasons will be carried out by Licensee at its expense, and appropriately verified proof of recordation will be promptly furnished to PHS. 	 

  

	 	14.16	Paragraphs 4.3, 8.1, 9.5-9.7, 12.1-12.5, 13.9, 13.10, 14.12, 14.13, and 14.16 of this Agreement shall survive termination
of this Agreement. 	 


  
 Page 17 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	14.17	The terms and conditions of this Agreement shall, at PHS’ sole option, be considered by PHS to be withdrawn from Licensee’s
consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee and a fully executed original is received by PHS within
sixty (60) days from the date of PHS signature found at the Signature Page. 

 SIGNATURES BEGIN ON
NEXT PAGE 

  
 Page 18 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 PHS PATENT LICENSE AGREEMENT – EXCLUSIVE

 SIGNATURE PAGE 
 For PHS : 

					
			
	/s/ Steven M. Ferguson	 		 	6/11/07
	 Steven M. Ferguson
 Director,
Division of Technology Development and Transfer
 Office of Technology Transfer
 National Institutes of Health
  

Mailing Address for Agreement notices:
  

Chief, Monitoring & Enforcement Branch, DTDT
 Office of Technology Transfer
 National Institutes of Health

6011 Executive Boulevard, Suite 325
 Rockville,
Maryland 20852-3804 U.S.A.
	 		 	Date

 For Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the contents of
any statements of Licensee made or referred to in this document are truthful and accurate.): 
  

					
	By: GlobeImmune, Inc.	 		 	
			
	/s/ Timothy C. Rodell	 		 	12 June 07
	Signature of Authorized Official	 		 	
			
	Timothy C. Rodell, M.D.	 		 	 
	 Printed Name
  

President & Chief Executive Officer
	 		 	
	Title	 		 	

  

	 	I.	Official and Mailing Address for Agreement notices: 

 1450 Infinite Drive 
 Louisville, CO 80027 

 
  

 
  

  
 Page 19 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  


	 	II.	Official and Mailing Address for Financial notices (Licensee’s contact person for royalty payments) 


Jeff
Dekker                             

Name 
 Senior Director, Finance         
 Title 
 Mailing Address: 

1450 Infinite Drive                

 Louisville CO 80027             

  
  

 
  

Email Address:
jeffdekker@globeimmune.com                     
 Phone:
1-303-625-2744                  
   
 Fax: 1-303-625-2710                     
 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this
Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. § 1001 (criminal liability including fine(s) or imprisonment). 

  
 Page 20 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
 [*] 

  
 Page 21 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	Licensed Fields of Use: 


(a) Development and use Licensee’s proprietary recombinant yeast technology (known as “Tarmogens”) expressing CEA
for the prevention and treatment of cancer 
  

	II.	Licensed Territory: 

  

	 	(a)	Worldwide 


  
 Page 22 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX C — ROYALTIES 

Royalties: 
  

	I.	Licensee agrees to pay to PHS [*] royalty in the amount of [*] 

 This [*] royalty shall be paid by Licensee [*] 
  

	II.	Licensee agrees to pay to PHS [*] royalty in the amount of [*] 


 

	III.	Licensee agrees to pay PHS earned royalties of [*]. 

  

	IV.	Licensee agrees to pay PHS Benchmark royalties, within [*] of achieving each Benchmark: 


[ * ] 
  

	V.	Licensee agrees to pay PHS [*] royalties of [*] 


  
 Page 23 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

Licensee agrees to use commercially reasonable efforts to satisfy the Benchmarks listed below. 

The development timeline and the commercialization of Tarmogen products expressing CEA as an antigen for the therapeutic treatment of human diseases will
depend on a variety of factors, some of which may be difficult to predict due to unforeseen problems. Nevertheless the general timelines the Licensee hopes to achieve are outlined below. If a change in regulatory guidelines, opinions or
standards, if a new standard of care is introduced during the development which affects the development strategy for this molecule, or if there are unexpected findings (safety or efficacy) in [*], the parties shall amend the timelines accordingly as
provided in Paragraph 9.2 of this Agreement. 
 The estimated cumulative time frames for initiation of these activities are from [*]


  
 Page 24 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

RESEARCH, DEVELOPMENT AND MARKETING PLAN 

The following Commercial Development Plan will be followed to develop and commercialize products based upon the licensed technology. 

1. Indication(s) targeted: 
 The
Licensee will pursue oncology indications driven by over expressed carcinoembryonic antigen (CEA) as scientific/clinical data and financial resources allow. 
 For example CEA is over-expressed in a number of epithelial ductal cancers, such as: 
  

	 	•	>90% of colorectal, gastric and pancreas cancers 

  

	 	•	70% of NSCLC 

  

	 	•	50% of breast cancer 

  

	2.	[*] 

  

	2.	[*] 

  

	3.	[*] 

  

	4.	[*] 


  
 Page 25 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX F – EXAMPLE ROYALTY REPORT 

Required royalty report information includes: 
  

	•	OTT license reference number (L-XXX-200X/0) 


 

	•	Reporting period 

  

	•	Catalog number and units sold of each Licensed Product (domestic and foreign) 


 

	•	Gross Sales per catalog number per country 

  

	•	Total Gross Sales 

  

	•	Itemized deductions from Gross Sales 

  

	•	Total Net Sales 

  

	•	Earned Royalty Rate and associated calculations 

  

	•	Gross Earned Royalty 

  

	•	Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 


 

	•	Net Earned Royalty due 

 Example

  

																	
	 Catalog Number
	  	Product Name	 	  	Country	 	  	Units Sold	 	  	Gross Sales
(US$)	 
	 1
	  	 	A	  	  	 	US	  	  	 	250	  	  	 	62,500	  
	 1
	  	 	A	  	  	 	UK	  	  	 	32	  	  	 	16,500	  
	 1
	  	 	A	  	  	 	France	  	  	 	25	  	  	 	15,625	  
	 2
	  	 	B	  	  	 	US	  	  	 	0	  	  	 	0	  
	 3
	  	 	C	  	  	 	US	  	  	 	57	  	  	 	57,125	  
	 4
	  	 	0	  	  	 	US	  	  	 	12	  	  	 	1,500	  
	 Total Gross Sales
	   
	  	 	153,250	  
	 Less Deductions:
	   
	  				  			
	 Freight
	   
	  	 	3,000	  
	 Returns
	   
	  	 	7,000	  
	 Total Net Sales
	   
	  	 	143,250	  
		
	 Royalty Rate
	   
	  	 	8	% 
	 Royalty Due
	   
	  	 	11,460	  
	 Less Creditable Payments
	   
	  	 	10,000	  
	 Net Royalty Due
	   
	  	 	1,460	  


  
 Page 26 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007] 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

 APPENDIX G – ROYALTY PAYMENT OPTIONS 

NIH/PHS License Agreements 

*In order to process payment via Electronic Funds Transfer sender MUST supply the following information: 

Procedure for Transfer of Electronic Funds to NIH for Royalty Payments 
 [*] 
 Mailing Address for Royalty Payments: 

National Institutes of Health 
 P.O. Box 360120

 Pittsburgh, PA 15251-6120 USA 

Overnight Mail for Royalty Payments only 
 National Institutes of Health 
 360120 
 Mellon Client Service Center 
 Room 670 
 500 Ross Street 
 Pittsburgh, PA 15262-0001 

(412) 234-4381 (Customer Service) 
 Please make checks payable to: NIH/Patent Licensing 
 The OTT _Reference
Number MUST appear on checks, reports and correspondence 

  
 Page 27 of
27    [Final]    [GlobeImmune, Inc.]    [June 11, 2007]